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                        Remarkable advances in the understanding of neoplastic progres-
sion at the cellular and molecular levels have spurred interest in 
molecularly targeted cancer therapeutics. New imaging and bio-
assay technologies are providing the basis for developing biomarkers 
that will facilitate development of these molecularly targeted drugs. 
Biomarkers may be used in early drug development to elucidate the 
mechanism of action of a drug and provide preliminary evidence of 
its effect. As the relationship between a drug or class of drugs and a 
biomarker becomes better understood, there is hope that clinical 
assays can be developed to identify patients most likely to benefit 
from the drug. These biomarkers are termed predictive biomarkers. 
Although prognostic biomarkers that provide information on the 
natural course of disease after standard treatments are useful, pre-
dictive biomarkers are of greater value in clinical decision making 
and will be essential tools for tailoring treatments. 
  Drug and assay developers, regulators, and clinical investigators 
face many dilemmas in the course of developing targeted drugs and 
associated predictive biomarkers. Difﬁ  cult choices must be made 
regarding use of precious resources (eg, biospecimens and funds) in 
selecting appropriate candidate biomarkers and determining opti-
mal study design. These choices will be inﬂ  uenced by many factors, 
including the anticipated business model for the biomarker assay 
(eg, development as a commercial kit or as a service laboratory test) 
and the inherent tension between rapidly determining whether any 
patient group beneﬁ  ts from the new drug vs accurately deﬁ  ning in-
dividual patients most likely to beneﬁ  t. Perhaps the most difﬁ  cult 
scientiﬁ  c and business decisions in drug and predictive biomarker 
development involve whether to use biomarkers to determine 
patient eligibility for inclusion in clinical studies assessing beneﬁ  t 
from a new agent. Using a predictive biomarker to select patients 
can lead to efﬁ  cient clinical studies if the biomarker is highly sensi-
tive and speciﬁ  c for beneﬁ  t. But these studies may not produce the 
information required to demonstrate efﬁ  cacy of the drug in an un-
selected patient population or to adequately characterize the perfor-
mance of the biomarker. Recognition of the fact that single 
biomarkers may not adequately reﬂ  ect the biology of cells has led to 
increasing use of panels of markers or multianalyte markers. 
Development and evaluation of these multianalyte biomarkers are 
more complicated than for single biomarkers, but the principles of 
development are much the same; for this reason, we do not speciﬁ  -
cally discuss them in this report. 
  The National Cancer Institute, the US Food and Drug 
Administration (FDA), and representatives of the drug and bio-
marker industry convened a workshop on October 29  –  30, 2007, in 
Bethesda, Maryland, to address the challenges facing biomarker 
development and drug and biomarker codevelopment. The goal of 
this meeting was to consider strategies to assist the research and 
development community in identifying and addressing issues in 
predictive biomarker development. This article builds on the discus-
sions that took place at the meeting and presents a set of issues for 
consideration and proposed development paths. These issues and 
concepts have been organized graphically in a ﬁ  gure (  Figure 1  ).         
    Design of the Workshop 
  The workshop began with an overview session that included presen-
tation of two case studies with different clinical study design strategies 
for evaluating a targeted therapy and its companion predictive bio-
marker. The presentations reviewed some of the lessons learned from 
past efforts to develop a targeted drug and companion biomarker and 
highlighted some critical issues to be addressed. The first case study 
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    A workshop sponsored by the National Cancer Institute and the US Food and Drug Administration addressed past lessons 
learned and ongoing challenges faced in biomarker development and drug and biomarker codevelopment. Participants agreed 
that critical decision points in the product life cycle depend on the level of understanding of the biology of the target and its 
interaction with the drug, the preanalytical and analytical factors affecting biomarker assay performance, and the clinical disease 
process. The more known about the biology and the greater the strength of association between an analytical signal and clinical 
result, the more efficient and less risky the development process will be. Rapid entry into clinical practice will only be achieved 
by using a rigorous scientific approach, including careful specimen collection and standardized and quality-controlled data col-
lection. Early interaction with appropriate regulatory bodies will ensure studies are appropriately designed and biomarker test 
performance is well characterized. 
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            Figure 1    .        Considerations for drug and biomarker codevelopment. The 
schematic encompasses the entire life cycle for codevelopment of a drug 
and biomarker combination from early selection and validation of the 
biomarker target through preclinical and nonclinical development of the 
drug and biomarker assay to clinical evaluation of the drug and biomarker 
assay combination. The center of the diagram lists major steps in the 
process for the biomarker and assay (left) and the drug (right). The boxes 
on the left list considerations for the biomarker and biomarker assay at the 
various phases of development. The boxes on the right list considerations 
for the drug and drug  –  biomarker diagnostic combination. The consider-
ations include recommendations for moving development forward and 
factors that should be taken into account in formulating the development 
strategy. As an assay and agent progress through the phases of develop-
ment, continued codevelopment depends on greater conﬁ  dence in the 
robustness and performance characteristics of the assay and stronger 
evidence for correlation of the biomarker with clinical beneﬁ  t from the 
agent. At each stage in the development process, there may be different 
expectations for the marker (its “ﬁ  tness for purpose”); as development 
progresses, so do the risks and therefore the expectations and require-
ments for the marker increase. FDA = Food and Drug Administration.         jnci.oxfordjournals.org    JNCI | Commentaries 1455
described development of HER2       as a predictive biomarker for 
patients who were likely to respond to trastuzumab (Herceptin). The 
second case study described ongoing research to identify and evaluate 
predictive biomarkers and biomarker assays for response to epidermal 
growth factor receptor (EGFR) inhibitors. These case studies are 
summarized in Boxes 1 (HER2) and 2 (EGFR).                         
  A key difference in the development paths followed in these two 
examples is that a biomarker-enrichment design strategy was used in 
the case of HER2-trastuzumab (only patients whose tumors tested 
positive for HER2 were entered into the pivotal phase III trial of 
trastuzumab and in most of the earlier trials). An enrichment 
strategy was not uniformly applied in the clinical trials evaluating the 
therapeutic agents targeting EGFR. Some trials of EGFR anti-
bodies enrolled patients based on EGFR expression detected by 
immunohistochemical analysis but many trials of EGFR inhibitors 
enrolled patients without preselection by EGFR status. 
  Workshop participants divided into three breakout groups to 
consider different aspects of predictive biomarker development: 1) 
feasibility studies and choice of assay and biomarker, 2) study 
design and clinical utility evaluation  —  for drug, biomarker, drug 
and biomarker, and 3) decision points and their implications. 
Summary reports from the three groups were presented to all par-
ticipants and recommendations were then discussed. These reports 
form the basis for this article and its recommendations.   
    Factors to Consider for Biomarker and Drug 
Codevelopment 
  A recurring theme in the workshop  ’  s discussions was the need to 
increase understanding of the biology associated with the chosen 
biomarkers, including their role in tumor behavior and their inter-
play with the drugs  ’   mechanisms of action. This biological under-
standing must be integrated into the clinical context in which the 
biomarker would be used (Boxes 1 and 2). Critical factors to this 
understanding are access to well-annotated biospecimens, early 
attention to characterization of the biomarker and standardization 
of assay methods, clinical trial designs that allow early evaluation 
of the effectiveness of the biomarker in predicting responsiveness 
to the drug, and ability to incorporate advancing technology and 
emerging data suggesting new or additional biomarkers that better 
characterize the target populations. 
  Sound biomarker and drug codevelopment depends on preclin-
ical data that would support use of a biomarker assay in therapeutic 
decision making and reliable information that would allow devel-
opment of a robust and reproducible assay. The clinical and labo-
ratory data providing a rationale for codevelopment should show 
consistent associations between biomarker status and the drug’s 
activity. The method(s) of detecting the biomarker in clinical spec-
imens should show reasonable analytical and clinical performance. 
Furthermore, the proportion of patients who are likely to beneﬁ  t 
from treatment, and the magnitude of the beneﬁ  t, should be sufﬁ  -
cient to warrant use of the biomarker. If only a fraction of the 
patients with a particular cancer that is diagnosed by standard 
methods may beneﬁ  t from treatment but the magnitude of beneﬁ  t 
is clinically important, then the codevelopment of a biomarker to 
identify those patients, if feasible, would be warranted.   
    Feasibility Studies and Choice of Assay and 
Biomarker 
    Biological Rationale 
  A biological rationale supported by research or observational data 
is a critical factor in selecting candidate predictive biomarkers for 
codevelopment with a cancer therapeutic. This would include evi-
dence that the biomarker(s) chosen is meaningfully correlated with 
the activity of the targeted agent (  41  ). The evidence may derive 
from existing preclinical and clinical literature; data collected 
during phase I, expanded phase II, or even early phase III clinical 
studies of the agent; or modeling and biological inferences using 
incomplete or partially complete provisional datasets and data 
mining. All available information on cellular pathways relevant to 
drug action, mechanisms, or drug interactions should be included 
in decision making and in generation of study hypotheses.   
    Technical Feasibility 
  A robust technology for testing in clinical samples must be avail-
able or it must be technically and economically feasible to develop 
an analytically reliable testing system on a timeline consistent with 
the development timeline for the drug. Definitive work on estab-
lishing even preliminary hypotheses may be at risk if reliable assay 
performance has not been achieved early in the decision-making 
process. In pilot work, real-world test performance and cost should 
all be considered important factors in determining the viability of 
biomarker testing. The anticipated strength of the association 
between biomarker status and drug benefit and the impact that use 
of the biomarker would have on the size of further clinical studies 
required for the drug development and approval process will likely 
play a role in the decision regarding whether to pursue codevelop-
ment of a drug and a biomarker.   
    Standardized Procedures for Specimen and Data 
Collection and Interpretation 
  There is increasing appreciation that assay performance can be 
greatly affected by preanalytic factors, including methods used for 
sample collection, handling, processing, transport, and storage. 
Physiological, pharmacological, and pathological features of patients, 
ranging from underlying patient comorbidities to patient drug treat-
ments, can be the source of spurious biomarker results. Information 
on these potential confounders should be gathered as comprehen-
sively as possible, and attention should be paid to whether the assay 
will be robust enough in the real world of sample procurement. 
  It is critical that standards for test performance be developed and 
adopted. This need has been addressed by FDA in a concept article 
on drug and diagnostic codevelopment and in a series of guidance 
documents (  42    –    47  ). To ensure success, there must be access to sys-
tematically collected, well-annotated, well-preserved patient speci-
mens with linked outcome data. This requires that sufﬁ  cient sample 
collection be prospectively built into studies and that standard pro-
tocols for collecting the samples and clinical information be imple-
mented. Use of a certiﬁ  cation process or reimbursement incentives 
to promote standardization of sample collection, handling, and 
preservation might help address these issues. Complete and consis-
tent reporting of the data and analysis of results generated in studies 
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    Box 1.         HER2 case study 
  Basic biology
      
    •         HER2/neu is a member of the human ErbB family of receptors, a group of transmembrane receptors with intracellular tyrosine 
kinase activity and extracellular binding domain.   
    •         HER2 receptor does not appear to have a speciﬁ  c ligand but can signal by forming heterodimers with other members of the ErbB 
family.   
    •         Ampliﬁ  cation of the   HER2   gene produces overexpression of this cell membrane receptor protein and activation of several 
downstream signal transduction pathways.   
    •         Studies in   HER2  -transfected cells, as well as transgenic animals, support the hypothesis that ampliﬁ  cation 
and/or overexpression of this proto-oncogene contributes to the pathogenesis and clinical aggressiveness of tumors (  1  ,  2  ).  
    •         HER2 is overexpressed in approximately 20%  –  30% of human breast cancers (  3    –    5  ). Overexpression rarely occurs in the absence 
of gene ampliﬁ  cation in breast cancer (ie, in approximately 3% of cases).     
      
  Clinical observations
      
    •         HER2 overexpression identiﬁ  es a subgroup of breast cancer patients with aggressive disease, frequently hormone receptor  – 
negative with poor prognosis (  3  ).   
    •           HER2   gene ampliﬁ  cation has been associated with resistance to a variety of cytotoxic agents and endocrine   therapies (  6  ,  7  ).     
      
  Agent description
      
    •         Trastuzumab (Herceptin) is a humanized monoclonal antibody with high speciﬁ  city for the HER2 protein.   
    •         Trastuzumab has demonstrated antitumor activity when used as a single agent in ﬁ  rst- or second-line treatment 
of   HER2  -ampliﬁ  ed or HER2-overexpressing metastatic breast cancer (  8  ,  9  ).     
      
  Development path and clinical trial design(s)
      
    •         Given strong laboratory and clinical data supporting the importance of the target and antitumor activity noted from target 
inhibition, clinical development of trastuzumab was initially focused on testing the agent in breast cancer patients with HER2 
overexpression and/or   HER2   ampliﬁ  cation in their tumors.   
    •         Trastuzumab received Food and Drug Administration approval in 1998 for the treatment of HER2-overexpressing metastatic 
breast cancer, as a single agent or in combination with paclitaxel, in patients who have received one or more chemotherapy 
regimens.   
    •         In 2006, trastuzumab was approved for adjuvant treatment of HER2-overexpressing breast cancer, either in combination with 
doxorubicin, cyclophosphamide, and paclitaxel or as a single agent following chemotherapy based on striking results from pivotal 
phase III trials (  10    –    14  ).   
    •         Detection of HER2 protein overexpression by immunohistochemistry (IHC) or   HER2   gene ampliﬁ  cation by ﬂ  uorescence in situ 
hybridization (FISH) was advised for selection of patients for trastuzumab therapy.     
      
  Assays (trade name of assay, what was measured, method, manufacturer)
      
    •         HercepTest, HER2 protein (A085 polyclonal antibody), IHC; Dako, Carpinteria, CA.   
    •         Pathway, HER2 protein (CB11 monoclonal antibody), IHC; Ventana Medical Systems      , Tucson, AZ.   
    •         PathVysion,   HER2   gene, FISH; Abbott Laboratories, Abbott Park, IL.   
    •         INFORM,   HER2   gene, FISH; Ventana Medical Systems, Tucson, AZ.   
    •         SPoT-Light,   HER2   gene, chromogenic in situ hybridization (ISH); Invitrogen, Carlsbad, CA.   
    •         EnzMet GenePro,   HER2   gene, silver-enhanced ISH; Ventana Medical Systems, Tucson, AZ.     
      
  Issues
      
    •         Debate continues about the optimal assay methodology and potential efﬁ  cacy of trastuzumab in patients who do not express 
HER2 (  15    –    19  ).         
use are also critical to allow appropriate interpretation and design of 
subsequent clinical trials. In this regard, the REMARK Guidelines 
prepared by the National Cancer Institute  –  European Organization 
for Research and Treatment of Cancer Working Group on Cancer 
Diagnostics (  48  ) and the Standards for Reporting of Diagnostic 
Accuracy initiative (  49  ) may be of considerable value. 
  There are limitations imposed by informed consent documents 
and institutional review boards on patient sample collection, 
storage, and use. An effective, clear, and simpliﬁ  ed informed con-
sent process needs to be developed and widely adopted for the 
purpose of permitting the use of archived biospecimens and asso-
ciated clinical information in biomarker research.   jnci.oxfordjournals.org    JNCI | Commentaries 1457
    Box 2.         Epidermal growth factor receptor (EGFR) case study 
  Basic biology
      
    •         EGFR is a member of the human ErbB family of receptors.   
    •         Upon ligand binding, EGFR homodimerizes or heterodimerizes with another member of the ErbB receptor family, activating 
its protein tyrosine kinase domain and initiating downstream signaling via cellular pathways controlling proliferation, survival, 
motility, and angiogenesis (  20    –    22  ).   
    •         EGFR is expressed in a variety of malignancies, and experimental evidence suggests that its inhibition can induce tumor stasis or, 
less commonly, regression (  20  ,  21  ).   
    •         Most frequent EGFR abnormality reported in human cancers is receptor overexpression, but unlike HER2, which is in the same 
family of receptors, high concordance between overexpression and gene ampliﬁ  cation has not been well demonstrated.   
    •         At the time of initial clinical trials evaluating EGFR inhibitors, gene ampliﬁ  cation and/or mutations were known to occur in 
glioblastoma but not in other tumor types, and markers of sensitivity or resistance were not known.   
    •         After antibodies and small molecules were commercially available, additional potential predictive biomarkers emerged, including 
  EGFR   gene ampliﬁ  cation or increased copy number by ﬂ  uorescence in situ hybridization (FISH), activating   EGFR   mutations in 
lung cancer patients and   KRAS   mutations that predicted lack of response to EGFR inhibition in colorectal and lung carcinomas.     
      
  Clinical observations
      
    •         EGFR overexpression determined by immunohistochemistry has been associated with poorer clinical outcomes in some settings (  20  ).   
    •         High   EGFR   gene copy number identiﬁ  ed by FISH might be a better predictor for survival in tyrosine kinase inhibitor (TKI)  – 
treated non  –  small cell lung cancer (NSCLC) patients (  23  ,  24  ).   
    •         Clinical evidence suggests that EGFR inhibition can induce tumor stasis or regression (  20  ,  25    –    27  ).   
    •         Speciﬁ  c somatic mutations, small deletions, insertions, or point missense mutations in the EGFR tyrosine kinase correlate with 
better prognosis and increased objective response rate in NSCLC patients treated with small   molecule TKIs (  25    –    28  ) but not 
with cetuximab (  29  ).   
    •           KRAS   mutations appear to predict for insensitivity of tumors to both antibodies and small molecules (  30    –    34  ).     
      
  Agent description
      
    •         Monoclonal antibodies, such as cetuximab and panitumumab, and TKIs, such as erlotinib and geﬁ  tinib, targeting EGFR have 
been developed.     
      
  Development path and clinical trial design(s)
      
    •         Given the paucity of biological information about markers of sensitivity and/or resistance, initial clinical trials focused on cancers 
that frequently express EGFR, but did not exclude patients with tumors that did not express EGFR.   
    •         Monoclonal antibodies were initially evaluated in colorectal and head and neck carcinoma patients, and the initial development of 
small molecule TKIs focused on non  –  small cell lung cancer as initial signals of activity were seen in these settings.   
    •         Evaluations of monoclonal antibodies in colorectal carcinoma have generally required EGFR protein expression as detected by 
  immunohistochemistry for eligibility; however, EGFR expression has generally not been required for enrollment into trials of 
inhibitors of EGFR tyrosine kinases.     
      
  Assays (trade name of assay, what was measured, method, and manufacturer)
      
    •         pharmDx, EGFR protein, IHC; Dako, Carpinteria, CA.   
    •         HTScan EGFR-phosphorylated protein, IHC; Cell Signaling Technology, Beverly, MA.   
    •         CONFIRM EGFR, EGFR protein, IHC; Ventana Medical Systems, Tucson, AZ.   
    •         PathVysion,   EGFR   gene (Locus Speciﬁ  c Identiﬁ  er for EGFR labeled with Spectrum Orange and Chromosome Enumeration 
Probe 7 labeled with Spectrum Green), FISH, Abbott Laboratories, Abbott Park, IL.     
      
  Issues
      
    •         Detectable EGFR (high expression not necessarily critical) appears to correlate with clinical beneﬁ  t from EGFR inhibitors 
in some cases but fails to provide predictive information in others. It is unclear whether these differences are due to test 
methodologies, the biology of the disease being evaluated, or a combination of both (  35  ,  36  ).  
    •           EGFR   mutations that occur more frequently in East Asian patients and never smokers are associated with improved response 
rate and outcome and rarely occur with   KRAS   mutations (  37    –    39  ). Patients with   EGFR   mutations may develop resistance through 
emergence of secondary mutations or   c-MET   ampliﬁ  cation (  40  ).   
    •           KRAS   mutations are associated with lack of activity of EGFR antibodies in colorectal carcinoma and perhaps in NSCLC although 
data are less deﬁ  nitive because of limited samples analyzed retrospectively from randomized clinical trials (  30    –    34  ).         1458   Commentaries | JNCI  Vol. 101, Issue 21  |  November 4, 2009
    Timing of Biomarker Development and Drug Development 
  Because advances in understanding the biology of cancer and in 
technologies for biomarker assays take place continuously, the 
decision to develop a companion biomarker may occur at any time 
during drug development, that is, from preclinical investigations to 
postmarketing studies conducted after approval of the drug. In 
ideal circumstances, the biomarker assay should be defined and 
validated by the end of phase II for definitive evaluation in phase 
III. However, this may often not be possible. There is also some 
risk to investing too much on biomarker development early in the 
drug development process because the biomarker may be irrele-
vant if the drug does not effectively inhibit the target or if the 
target is not related to cancer progression in the clinical setting in 
which it is tested. It is also possible that the putative target of the 
agent may be shown to be wrong in early clinical testing, which 
could result in effort and resources being wasted on development 
of a biomarker that would not be relevant. Alternative approaches 
for iterative biomarker discovery, design, and validation may need 
to be considered (see “Study Design and Clinical Utility Evaluation      ” 
section below). 
  The HER2 and EGFR inhibitor case studies highlight two 
extremes in the spectrum of potential strategies for biomarker and 
drug       codevelopment. As described in Box 1, a wealth of preclinical 
and clinical biological data were available to provide the rationale 
for codeveloping trastuzumab and an assay for HER2 in the treat-
ment of breast cancer, including information on use of HER2 as a 
prognostic marker, data from laboratory experiments linking am-
pliﬁ  cation and/or       expression of HER2 to development of breast 
cancer, and sensitivity of HER2 to blocking antibodies (  3  ). In ad-
dition, adequate, although not optimal, assays for HER2 existed, 
and it was economically advantageous to initiate agent develop-
ment in the smaller subpopulation of   HER2  -ampliﬁ  ed breast can-
cer patients. Thus, for trastuzumab, there was a critical mass of 
information to support the development of the agent in a patient 
subpopulation identiﬁ  able with a biomarker assay. 
  As suggested in Box 2, the situation for EGFR inhibitors has 
been less straightforward. Conﬂ  icting data exist on the frequency 
of expression or overexpression of EGFR and its association with 
clinical outcomes (  20  ,  21  ). Laboratory data do not suggest that 
EGFR protein overexpression is tightly associated with the anti-
cancer effects of EGFR inhibitors (  35  ,  36  ). For example, some cell 
lines with low levels of protein expression are sensitive to EGFR 
inhibition and others with high expression are resistant. 
  Although cut points and scoring systems based on EGFR 
protein expression have often been used for patient selection for 
EGFR inhibitor therapy in clinical trials, this practice is not well 
supported by clear and consistent clinical or laboratory data. The 
pivotal positive trial of erlotinib that led to its approval for treat-
ment of patients with locally advanced or metastatic non  –  small cell 
lung cancer after failure of at least one prior chemotherapy reg-
imen was conducted in unselected patients (  50  ). Retrospective 
analyses of results from this study examining a variety of EGFR 
assays failed to identify subsets of patients that did or did not ben-
eﬁ  t from treatment with this EGFR inhibitor (  23  ). 
  Once comprehensive information is gathered on the biology of 
a biomarker and the analytical performance and practical aspects of 
using a particular assay (eg, cost, accessibility, stability of analyte 
under conditions of collection, and use), a decision can be made 
whether to incorporate the biomarker into further clinical 
studies.     
    Study Design and Clinical Utility 
Evaluation  —  Drug, Biomarker, and 
Drug  –  Biomarker Combination 
  The intended use of a biomarker must be clearly defined, and the 
effectiveness and safety data should support the biomarker and its 
assay for this use. In general, the safety of a biomarker assay is re-
lated to the clinical impact of false-positive or false-negative test 
results (  51  ). Limitations and uncertainties should be described. 
  There are several strategies for assessing biomarkers and as-
says for their ability to predict effectiveness of treatment and 
several choices of trial designs for demonstrating that the bio-
marker is informative in making treatment decisions. To most 
efﬁ  ciently achieve success in meeting regulatory requirements for 
safety and effectiveness of the biomarker and drug combination, 
dialog with FDA early in the development of the biomarker and 
coordination of regulatory work across multiple FDA centers may 
be helpful (  42  ). 
    Enrichment Designs Used to Evaluate Treatment Effect 
  Clinical trial strategies for biomarker and therapeutic develop-
ment may be broadly divided into enrichment and all-comers 
designs. Enrichment studies (eg, studies performed solely in bio-
marker-positive patients or only in biomarker-negative patients 
for toxicity or resistance signals) may expedite collection of data 
to demonstrate safety and efficacy of the diagnostic  –  drug combi-
nation compared with existing treatments or placebo. This ap-
proach can facilitate rapid and cost-effective market entry. 
Enrichment studies may be preferred when the biomarker of in-
terest is well understood biologically and analytically, and the 
supporting data suggest little benefit of the drug in biomarker-
negative populations or suggest substantial drug toxicity or resis-
tance in biomarker-positive patients. When efficacy is tested only 
in biomarker-positive patients, postmarketing studies of biomark-
er-negative patients to understand the full spectrum of drug 
utility are valuable but may be challenging. There will always be 
limitations on how far preclinical and early clinical trial results 
can be extrapolated to justify later steps in the drug and biomarker 
development paths. 
  Clinical trials in enriched populations must be designed with 
appropriate control groups to identify both the prognostic and 
predictive value of the biomarker to determine the potential clinical 
utility of the test for selecting a speciﬁ  c treatment (  52  ). If the bio-
marker is prognostic for clinical outcomes independent of treat-
ment, then results from single-arm studies may not have a historical 
reference for comparison. In some cases, imperfect understanding 
of the biomarker could lead to enrichment studies creating mis-
leading information on the utility of the drug. If only biomarker-
positive patients are studied, the sole performance characteristic of 
the biomarker that can be evaluated is whether or not the drug 
beneﬁ  ts biomarker-positive patients, and the behavior of the drug 
in biomarker-negative patients would be undeﬁ  ned. This leaves 
open the possibility that a new drug could be introduced into the jnci.oxfordjournals.org    JNCI | Commentaries 1459
market with restrictions. For example, although cetuximab was 
initially evaluated in enriched populations and approved for use 
only in patients with EGFR-positive tumors, it is becoming ap-
parent that some patients with EGFR-negative tumors, as assessed 
by immunohistochemistry, may beneﬁ  t (  29  ). Thus, the biological 
background on the biomarker suggesting that treatment beneﬁ  t 
will be limited to those positive for the biomarker must be very 
strong if one is to consider an enrichment strategy.   
    All-Comers Designs 
  An “all-comers” study design does not restrict entry into the clinical 
trial on the basis of biomarker status. Although the accrual of patients 
is prospective, the biomarker evaluation may be conducted either 
prospectively or retrospectively. The biomarker can be measured at 
trial entry and used for stratified randomization of patients to the 
treatment groups, or patients can be randomly assigned to treatment 
groups without stratification by marker status and biomarker assays 
can be conducted later on the banked biospecimens. For the latter 
situation, it is even possible that the biomarker assays could be con-
ducted many years later. If biomarker evaluation is not required for 
study entry and will be conducted later, it is important that the pro-
portion of patients from whom specimens are collected for assay is 
high. Otherwise, there may be questions about whether the group of 
patients for whom specimens and assay results are available is repre-
sentative of the full trial cohort. An advantage of requiring biomarker 
status for stratified randomization is that it ensures that biomarker 
results will be available for all patients who enter the trial, and it 
ensures balanced marker distribution between treatment groups. 
However, trials requiring up-front biomarker assay results can be 
logistically more difficult to conduct. For larger studies, major im-
balances in biomarker distributions between treatment arms are un-
likely to occur, and stratification becomes less important. 
  Investigators have explored the possibility of a two-step proce-
dure in which drug effect is evaluated ﬁ  rst in the total population 
without knowledge of biomarker results followed by evaluation of 
drug effect in a biomarker-deﬁ  ned subset, depending on the out-
come in the full group (  53  ,  54  ). If a two-step procedure is to be 
used, it should be speciﬁ  ed prospectively in the protocol. The plan 
should include a precise deﬁ  nition of the subset, speciﬁ  cation of 
the rule that will determine whether testing terminates with the 
full group or continues to the subset, and an indication of the sta-
tistical operating characteristics of the procedure. If a positive drug 
effect is found when analyzing the full patient cohort, this would be 
interpreted as indicating beneﬁ  t of the drug in the entire unse-
lected population. A negative study outcome in the full group 
would be followed by another statistical test for treatment beneﬁ  t 
according to biomarker status. If a statistically signiﬁ  cant treatment 
beneﬁ  t was observed in biomarker-positive patients, the results 
would indicate beneﬁ  t of the drug in this biomarker-selected popu-
lation. To account for the multiple tests and control the overall 
probability of reaching incorrect conclusions, a standard approach 
would be to distribute the typical testing type I error of .05 over the 
multiple tests. For example, an     -level of .04 could be allocated to 
the test of treatment effect in the overall patient cohort, and if 
biomarker exploration is subsequently needed, the remainder of 
the     -level (.01) can be applied to the test of treatment effect in the 
biomarker-selected subgroup. This means that the size of the study 
will have to be larger than it would have been if an enrichment 
design had been used up front with the full     -level of .05 allocated 
to the treatment comparison in the biomarker-selected subgroup. 
However, the two-step design offers valuable ﬂ  exibility if there is 
some uncertainty about how to best deﬁ  ne the biomarker-positive 
subgroup or if there is a possibility that the treatment has broad 
effects resulting in some beneﬁ  t to all patients, regardless of bio-
marker status. A potential danger noted in this two-step approach 
is that a drug beneﬁ  t observed in the entire population might be a 
consequence of the strength of response in the biomarker-positive 
subset rather than truly being a beneﬁ  t in the entire population. 
Nonetheless, an advantage of this design is that data will have been 
collected on biomarker-negative patients, and one could perform 
exploratory analyses to examine for possible treatment effects in 
the biomarker-negative subgroup. 
  To date, no studies using this two-step approach have been 
reported. Most reports of biomarker and therapeutic studies in the 
literature and most FDA-approved drug and biomarker assay com-
binations have been based on enrichment designs. These have 
been pragmatic and facile but have not occurred without surprises. 
For example, as noted above, cetuximab appears to beneﬁ  t both 
EGFR-positive and EGFR-negative patients when EGFR is 
assessed by immunohistochemistry (  29  ). Given the speciﬁ  city of 
the antibody for target, it is possible that the apparent beneﬁ  t to 
the immunohistochemically deﬁ  ned EGFR-negative group might 
reﬂ  ect the limitations of the assay or biomarker in deﬁ  ning the 
patients most likely to beneﬁ  t, although other biological explana-
tions continue to be explored.   
    Alternative Approaches 
  Other approaches using adaptive biomarker enrichment have been 
suggested (  55  ,  56  ). Adaptive clinical trial designs permit midtrial 
modifications, which are based on incorporating new interim 
information either from inside or outside the trial. Adaptive designs 
may be Bayesian (using previous information gathered outside of 
the trial updated with information collected in the trial), but do not 
have to be. The flexibility of adaptive designs permits changes 
during the conduct of the trial in features such as sample size, 
treatment allocation ratios, and the number of interim analyses, as 
well as the selection of treatments and doses. For example, using 
adaptive designs, patients enrolled in a drug intervention clinical 
trial could be classified initially on the basis of the presence or 
absence of selected sets of biomarkers. As new drug efficacy and 
biomarker data become available, those data could be used to 
change the probability that newly accrued patients receive certain 
treatments depending on their biomarker profiles. Adaptive 
designs, like any other design, must adhere to regulatory require-
ments for maintaining study integrity and patient safety. They 
need to be designed with specific operating characteristics in mind. 
For most study designs, this requires specification of type I and 
type II error rates; for Bayesian designs, more extensive evalua-
tions, often through a series of computer simulation studies, are 
required to fully evaluate their operating characteristics. 
  Other approaches, including biomarker-based strategies 
(  57  ,  58  ) and the two-step procedures described above (  53  ,  54  ) have 
recently been published. Further work in these areas should be 
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    Decision Points and Their Implications: 
Go  –  No Go Decisions for the Study of a 
Drug  –  Biomarker Combination 
  Pharmaceutical and device manufacturers working to market 
codeveloped products are urged to bring all the needed expertise 
to the development process, including FDA regulatory staff and 
third-party payers, to make the appropriate scientific and business 
decisions. These experts should be convened near the beginning 
of the process to ensure that challenges and obstacles are identi-
fied and addressed early in the product life cycle with minimum 
surprises and to consider novel business and marketing arrange-
ments to share both risks and rewards for development of these 
products. 
    The Timing of Decisions About Studying a 
Drug  –  Biomarker Combination 
  Consideration of the integration of biomarker development into 
the drug development process should occur as early as possible 
because of the implications for biospecimen and data collection. 
Early implementation of standardized procedures for biospeci-
men and clinical data collection and efforts devoted to character-
izing biomarker targets can maximize the utility of the specimens 
and provide information on the targets useful in addressing 
future questions regarding variations in biomarker expression or 
modulation. Decisions on how to study a biomarker in a partic-
ular clinical trial depend on the context of the study. Key consid-
erations include factors such as the need to collect safety data, 
availability of reliable assays for evaluating the biomarker and 
drug activity, and relationship of results to clinical benefit (see 
the “Preclinical and Nonclinical Development” and “Clinical 
Development” sections of   Figure 1  ).  
    Timing of Decisions Regarding Codevelopment of 
Biomarker Assays 
  A long lead time may be needed to develop well-characterized 
biomarker assays. The goal is to be prepared for phase III by 
ensuring that appropriate biomarker-based selection strategies 
are in place. For example, better-developed selection strategies 
might have more efficiently identified the positive effects of EGFR 
inhibitors in early phase III trials in patients with lung (  23  ,  50  ) and 
colorectal carcinomas (  31  ,  33  ,  34  ). 
  In some cases, practical business considerations may outweigh 
beneﬁ  ts of a science-based strategy because the incentives for pro-
ducing biomarker assays may be substantially misaligned for the 
diagnostics and pharmaceutical companies during different stages 
of development. The long time to market is a ﬁ  nancial risk and 
critical issue for both the pharmaceutical and diagnostics indus-
tries, but it is a higher risk for the diagnostics industry during early 
biomarker and assay development. At this stage, not much is 
known about the drug or the biomarker, and the chosen biomarker 
might not ultimately be suitable or the drug might not prove suf-
ﬁ   ciently effective to warrant full development. Well-annotated 
biospecimens collected using standard protocols and appropriate 
consents are critical to allow biomarker assay development to take 
place when there is sufﬁ  cient knowledge available about the drug 
and its relationship to the biomarker. The development of a shared 
repository of specimens from patients receiving the treatment of 
interest could help to address this need. 
  The lack of a rigorously evaluated biomarker at the end of 
phase II and the large sample size required to validate a biomarker 
assay increase the risk to the pharmaceutical company in later de-
velopment stages. Secondary approvals (cross-labeling studies)  — 
for example, taking a drug and biomarker       combination approved 
in a narrowly deﬁ  ned population into a second population or eval-
uating a second drug from the same chemical or mechanistic class 
in combination with a biomarker  –    –  are less risky for both drug and 
biomarker assay development. 
  The perceived market worth for drugs and biomarkers may also 
be mismatched. The drug developed with the biomarker is a value 
generator, whereas the diagnostic may be perceived as a com-
modity (sometimes offered at no cost by the pharmaceutical com-
pany). Higher reimbursement rates for diagnostic assays used in 
patient management would likely provide needed incentives to the 
diagnostics industry. 
  The FDA usually recommends validating biomarkers prospec-
tively to ensure study of appropriate populations, to minimize 
sampling bias, and to maximize the likelihood of having adequate 
power to evaluate the hypothesis being tested. This ideal study 
approach is most appealing if it can be performed in a time- and 
cost-efﬁ  cient manner. If timelines for studies are long, and if study 
size requirements are large, companies may be reluctant to involve 
themselves in the uncertain process of companion product devel-
opment, particularly in a competitive market with rapid changes in 
drugs, diagnostics, and clinical decision making. If companies were 
able to access well-constructed biological specimen collections and 
clinical data in early decision making, more robust biomarker-drug 
candidates and more focused phase III clinical studies might 
result. 
  If companies were able to develop well-planned incremental 
evaluations of drug-companion diagnostic pairs across phase I, II, 
and III studies that provide for better product decision making or 
in terms of trial design and size, the cost  –  beneﬁ  t of these incre-
mental evaluations could potentially revolutionize the develop-
ment pipeline for new drugs and diagnostics. Unfortunately, it is 
too early to fully understand the ﬁ  nancial costs and risks of this 
approach. 
  Well-planned incremental evaluations of drug-companion 
diagnostic pairs across phase I, II, and III studies that provide for 
better decision making in terms of trial design would ideally 
increase the efﬁ  ciency of the drug development process. However, 
limits to biological understanding and resources can make it 
difﬁ  cult to identify or carry out an optimal sequence of evalua-
tions in a prospective fashion. Retrospective biomarker analyses 
using specimens previously collected within treatment trials may 
also be helpful, either in the discovery process, in ﬁ  ne-tuning devel-
opmental plans, or in some cases in supporting submissions to the 
regulatory agencies. The potential biases, effects of multiplicity, 
missing data, and other deﬁ   ciencies of such analyses must be 
addressed. In addition, the statistical power for detecting biomarker 
effects in such retrospective studies will often be low. However, the 
results might identify promising new or improved biomarker assays 
that could be introduced into phase III studies. The FDA continues 
to seek input from the research and development community on jnci.oxfordjournals.org    JNCI | Commentaries 1461
these issues, but there is still no clear strategy for the approval of 
a predictive diagnostic with therapeutic agent using the retro-
spective approach (  59  ). 
  There are situations in which biomarker assay approvals may be 
based on retrospective analysis alone. For example, a safety bio-
marker assay might be approved based on retrospective analysis of 
biomarker-positive and biomarker-negative specimens from 
patients who have been treated with approved drugs and in whom 
the safety outcomes are known. Early consultation with FDA sci-
entists from both drug and device ofﬁ   ces is encouraged when 
considering these strategies.     
    Recommendations 
  The workshop participants addressed scientific, regulatory, and 
business-related issues that affect the success or lack thereof in 
developing biomarkers for clinical decision making. Discussions of 
lessons learned in the development processes for trastuzumab and 
the EGFR inhibitors made it clear that the more known about the 
biology of the biomarker and its relationship to the therapeutic 
agent, the easier it is to determine the clinical trial design most 
appropriate for evaluating the utility of the biomarker assay for 
predicting the clinical effects of the agent. Major challenges for 
biomarker assay and therapeutic agent codevelopment relate to the 
costs of standardizing and evaluating the utility of an assay when 
neither the clinical activity of the agent nor the relationship of the 
biomarker to the mechanism(s) of action of the agent being devel-
oped is clear. 
  The following recommendations were made to address the 
challenges identiﬁ  ed:
      
    1.         Consider the potential need for a predictive biomarker assay 
early in development of the therapeutic agent to facilitate coor-
dinated development of both biomarker assay and therapeutic 
agent.   
    2.         Build evidence from literature and preclinical, observational, and 
early clinical studies supporting a strong biological rationale for 
the biomarker and therapeutic agent interaction being predictive 
of therapeutic beneﬁ  t.   
    3.         Convene all the relevant diagnostic, pharmaceutical, and regula-
tory representatives early in the process to establish performance 
requirements, the developmental path and timeline, and go  –  no 
go decision points for the therapeutic agent and biomarker assay 
combination. Well-deﬁ  ned development goals and milestones 
should be established for effective go  –  no go decisions for both 
the therapeutic agent and the biomarker assay.   
    4.         Early discussions with scientists from the regulatory agencies are 
critical. The regulatory preference for data from prospective 
studies is often problematic for device developers. Alternative 
trial designs should be considered.   
    5.         Consider practical aspects of the proposed assay. Will the tech-
nology be robust, economical, and otherwise feasible in the 
proposed clinical setting?   
    6.         Consider specimen needs early to ensure that appropriate bio-
specimens are collected with consent for future research use and 
that they are handled and stored properly. Informed consents 
that allow for ﬂ  exibility in the future use of collected samples 
may be required.   
    7.         Efforts should be made to collect specimens in a standardized way 
throughout the biomarker assay and therapeutic agent develop-
ment process so that valid retrospective analyses can be carried 
out to facilitate assay performance and clinical utility evaluations.   
    8.         Careful plans for pathological and demographic data collection 
as well as clinical data are necessary for the biomarker evalua-
tions. The documentation regarding the collected specimens 
will be critical because clinical trials often extend for years and 
new technologies for marker measurements may be developed 
during this time. Well-planned specimen collection and docu-
mentation throughout the therapeutic agent development 
process (preclinical and clinical phases I, II, and III) could 
facilitate evaluation of biomarker assays retrospectively.     
      
  Finally, the misalignment of incentives for production of 
  biomarker assays vs therapeutic agents continues to hamper 
co  development of agents and biomarkers. The resolution of this 
problem is not straightforward but some suggestions were made. 
Higher reimbursement for diagnostic tests, particularly those that 
are required for choice of therapeutic, would probably provide 
additional incentive to the assay developer. The many challenges 
identiﬁ  ed during the discussions at the workshop and catalogued 
in this commentary and in   Figure 1   will take time and community 
effort to address. We focused on discussion of alternative trial 
designs, the need for early comprehensive planning, and consider-
ation of factors affecting business decisions for assay and drug 
  developers. We hope that this will serve as the beginning of a pro-
ductive dialog in the community.     
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